AU2014244235B2 — Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
Assigned to Pfizer Ireland Pharmaceuticals · Expires 2016-04-21 · 10y expired
What this patent protects
The invention relates to the sodium salt of (1R,2S,5R)-7-oxo-sulfooxy-1,6 diazabicyclo[3.2.1]octane-2-carboxamide in hydrated or anhydrous crystallised enantiomeric form and in particular in the novel crystallised polymorphic and pseudopolymorphic forms "A", "B", …
USPTO Abstract
The invention relates to the sodium salt of (1R,2S,5R)-7-oxo-sulfooxy-1,6 diazabicyclo[3.2.1]octane-2-carboxamide in hydrated or anhydrous crystallised enantiomeric form and in particular in the novel crystallised polymorphic and pseudopolymorphic forms "A", "B", "D" and "E" defined in the application, as well as the method of preparation. The compound of the invention can be used as a medicament, in particular a beta-lactamase inhibitor.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.